Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Healthy Participants
Interventions: AMG 510, Omeprazole; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Participants
Interventions: PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana

Conditions: Malignancies Multiple
Interventions: BMS-986205, Itraconazole, Rifampin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Panic Disorder
Interventions: Cognitive behavioral therapy, D-cycloserine; Behavioral · Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Hartford, Connecticut • Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: Midazolam Syrup, Midazolam Solution, Pirtobrutinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions: testosterone cypionate, finasteride, placebo injection, placebo pill; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 4
States / cities: Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more

Conditions: Genetics of Drug Metabolism
Interventions: Not listed
Lead sponsor: Renaissance RX; Industry
Eligibility: 18 Years and older
Enrollment: 250,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 49
States / cities: Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 39 more

Conditions: Recovery of Function (G11.427.698.620), Athletic Performance, Heart Rate Variability (HRV)
Interventions: Magnesium L-Threonate, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type II Diabetes, Cardiovascular Disease
Interventions: Intensive discharge intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystinuria
Interventions: Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, CYP 450 Substrates; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more

Conditions: Healthy Participants
Interventions: BMS-986165, Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sleep Deprivation
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Drug Interaction
Interventions: BIIB074, Valproic Acid; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 16
States / cities: Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more

Conditions: Breast Neoplasms, Musculoskeletal Pain
Interventions: Hypnosis, Attention Control; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Volunteer
Interventions: Mirdametinib, Mirdametinib and Carbamazepine; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Hypercholesterolemia, Diabetes, Medication Adherence
Interventions: Refill synch; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Psychiatric Disorder
Interventions: Pharmacogentic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Search by objective public record fields.

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

Diagnosing Adverse Drug Reactions Registry

Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes

Intensive Discharge Intervention in Diabetes

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

The Effect of Synching Prescription Refills on Adherence

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes